Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiwan Government Supports Creating Solid Clinical Trial Environment - DIA Exclusive 

This article was originally published in PharmAsia News

Executive Summary

BOSTON - Taiwan's Bureau of Pharmaceutical Affairs and Center for Drug Evaluation brought a large delegation to promote the country's clinical trial environment at the Drug Information Association's 44th annual meeting held this year in Boston. BPA Deputy-Director General Li-Ling Liu and CDE Executive Director Herng-Der Chern, spoke with PharmAsia News on the sidelines of the conference about the country's efforts to make Taiwan an attractive location for clinical development

You may also be interested in...



Taiwan To Establish Government-Run VC Fund, Biotech R&D Center

HONG KONG - Looking to shore up a weakness in its ability to transform research into commercially viable products and strengthen its position in the biotech and pharmaceutical sectors, the Taiwan government announced several measures in the past few weeks that will see it create a research and development center and a government-run venture capital fund

Taiwan To Establish Government-Run VC Fund, Biotech R&D Center

HONG KONG - Looking to shore up a weakness in its ability to transform research into commercially viable products and strengthen its position in the biotech and pharmaceutical sectors, the Taiwan government announced several measures in the past few weeks that will see it create a research and development center and a government-run venture capital fund

Lack Of Funding and Political Will Hinders Hong Kong’s Untapped Drug Discovery Research – ChinaBio Investor Forum

HONG KONG - Generally overshadowed by Singapore or Taiwan as a pharmaceutical and biotech center in Southeast Asia, Hong Kong has deep reserves of untapped knowledge and intellectual property

Related Content

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel